Corbus Pharmaceuticals Announces Pricing of Public Offering

Rhea-AI Summary

Corbus Pharmaceuticals (Nasdaq: CRBP) priced an underwritten public offering to raise approximately $75 million before underwriting discounts and expenses. The offering consists of 4,744,231 shares of common stock and pre-funded warrants to purchase 1,025,000 shares at $12.9999 each, with an exercise price of $0.0001 per share. Underwriters have a 30-day option for up to 865,384 additional shares. Closing is expected on or about November 3, 2025. Proceeds are intended to fund clinical development, working capital, and general corporate purposes.

Positive

• Gross proceeds of approximately $75 million
• Proceeds earmarked to fund clinical development
• Includes pre-funded warrants allowing near-term capital receipt

Negative

• Issuance of 4,744,231 shares plus warrants may cause share dilution
• Underwriting discounts and offering expenses will reduce net proceeds
• Offering closing is subject to customary conditions, not guaranteed

News Market Reaction

-26.09%

29 alerts

-26.09% News Effect

-14.3% Trough in 2 hr 39 min

-$71M Valuation Impact

$201M Market Cap

1.3x Rel. Volume

On the day this news was published, CRBP declined 26.09%, reflecting a significant negative market reaction. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $71M from the company's valuation, bringing the market cap to $201M at that time.

Data tracked by StockTitan Argus on the day of publication.

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total public offering size of approximately $75 million, before deducting underwriting discounts and estimated offering expenses. The exercise price of the pre-funded warrants is $0.0001 per share. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 865,384 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Corbus. The offering is expected to close on or about November 3, 2025, subject to customary closing conditions.

Corbus intends to use the net proceeds of the offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.

Jefferies LLC is acting as   the book-running manager for the offering. RBC Capital Markets, LifeSci Capital LLC, and Mizuho Securities USA LLC are acting as lead managers for the offering.

The offering is being made pursuant to a registration statement that was filed with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on March 20, 2024. Copies of the final prospectus supplement and accompanying prospectus relating to these securities may also be obtained, when available, at the SEC’s website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Corbus’ expectations regarding the completion, timing and size of its public offering and the anticipated use of proceeds therefrom. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Corbus’ business and finances in general, including the risks and uncertainties in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering that will be filed with the SEC and the Company’s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. There can be no assurances that we will be able to complete the proposed offering on the anticipated terms, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corbus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Corbus Pharmaceuticals Contacts: 

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

FAQ

What did Corbus (CRBP) announce on October 31, 2025?

Corbus announced an underwritten public offering to raise approximately $75 million via 4,744,231 common shares and pre-funded warrants.

How much is Corbus (CRBP) raising in the October 2025 offering?

The company priced the offering at roughly $75 million before underwriting discounts and estimated offering expenses.

What securities are included in Corbus's (CRBP) offering and at what price?

The offering includes 4,744,231 common shares at $13.00 each and pre-funded warrants for 1,025,000 shares at $12.9999 each; exercise price is $0.0001 per share.

When is the Corbus (CRBP) offering expected to close?

The offering is expected to close on or about November 3, 2025, subject to customary closing conditions.

What will Corbus (CRBP) use the offering proceeds for?

Corbus intends to use net proceeds to fund its clinical development programs, plus working capital and other general corporate purposes.

Is there an over-allotment option in Corbus's (CRBP) offering?

Yes. Underwriters have a 30-day option to purchase up to 865,384 additional shares on the same terms.

Who is managing the Corbus (CRBP) offering?

Jefferies LLC is the book-running manager, with RBC Capital Markets, LifeSci Capital, and Mizuho Securities USA as lead managers.